NCT03758417 - A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

January 23, 2019

Primary Completion Date

July 10, 2025

Study Completion Date

October 20, 2025

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL

LCAR-B38M CAR-T Cell

Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).

Trial Locations (11)

100191

Peking University Third Hospital, Beijing

200003

Shanghai Changzheng Hospital, Shanghai

200025

Ruijin Hospital, Shanghai Jiao Tong University, Shanghai

200434

Shanghai Fourth People Hospital, Shanghai

210008

Nanjing Drum Tower Hospital, Nanjing

210029

Jiangsu Province Hospital, Nanjing

310003

The First Affiliated Hospital, Medical School of Zhejiang University, Hangzhou

350001

Fujian Medical University Union hospital, Fuzhou

510060

Sun Yat -Sen University Cancer Center, Guandong

610041

West China Hospital, Sichuan University, Chengdu

710004

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an